Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2103 - Epidemiological study of histologically proven advanced hepatocholangiocarcinoma : an AGEO multicenter retrospective study

Date

09 Sep 2017

Session

Poster display session

Topics

Cancer Prevention;  Hepatobiliary Cancers

Presenters

Yann Touchefeu

Citation

Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369

Authors

Y. Touchefeu1, C. Prieux-Klotz2, D. Tougeron3, T. Lecomte4, M. Caulet4, T. Matysiak Budnik1, V. Hautefeuille5, M. Tiako-Meyo6, A. Zaanan7, M. Salimon1

Author affiliations

  • 1 Imad, Department Of Gastroenterology, Nantes University Hospital, 44093 - Nantes/FR
  • 2 Department Of Gastroenterology, Cochin University Hospital, 75014 - Paris/FR
  • 3 Department Of Gastroenterology, CHU Poitiers, Jean Bernard Hôpital, 86021 - Poitiers/FR
  • 4 Department Of Gastroenterology, CHU de Tours, Hôpital Trousseau, 37170 - Chambray-lès-Tours/FR
  • 5 Department Of Gastroenterology, CHU Amiens-Picardie Site Nord, 80054 - Amiens/FR
  • 6 Department Of Gastroenterology, Hôpital Européen Georges Pomipdou, 75015 - Paris/FR
  • 7 Department Of Gastroenterology, Hopital European Georges Pompidou, 75015 - Paris/FR
More

Resources

Abstract 2103

Background

Hepatocholangiocarcinoma (cHCC-ICC) is a rare primary hepatic tumor combining the features of cholangiocarcinoma and hepatocellular carcinoma. Few data about the epidemiology of cHCC-ICC have been reported, mainly from surgical series in Asian and American populations. The aim of this study was to evaluate epidemiological features and overall survival (OS) of histologically proven advanced cHCC-ICC patients.

Methods

Data from patients treated for histologically proven cHCC-ICC in six French university hospitals between 2008 and February 2017, were retrospectively collected. The main clinical, biological, treatment and follow up data were reported. Statistical analysis was performed using Graph Pad Prism 6.

Results

Thirty patients were included (76.6% of men, median age 64 years [extreme 37-88]). Cirrhosis was associated in 33.3% of cases (Child-Pugh score A: 70%). Positive serology for hepatitis B virus and C was found in respectively, 5 (16.6%) and 2 (6.6%) patients; with 1 co-infection. Chronic alcoholism was noted in 33.3%, diabetes and obesity were both present in 26.6% of cases. Alpha-fetoprotein, carbohydrate antigen 19-9 and carcinoembryonnic antigen serum levels were above normal in respectively 39% (median = 5.3 μg/L [2 – 21 479]), 50% (median = 21.8 IU/mL [4.5-20 000]) and 14% (median = 2.4 µg/L [2-88]) of cases. Six patients (20%) were initially treated by surgical resection. At the diagnosis of advanced disease, 66.6% of patients had multifocal hepatic lesions, 50% distant metastases (bone (23.3%), lung (20%), peritoneal metastases (13.3%)). Twenty-seven patients (90%) received first line of systemic treatment. Twenty-four patients were treated by chemotherapy: Gemcitabine (Gem) alone (n = 1), Gem+oxaliplatin (Gemox) (n = 12), Gemox + bevacizumab (n = 9), Gem+cisplatin (n = 2). Two patients received chemoembolization, 1 patient received sorafenib. Twenty-one (70%) and 4 (13.3%) patients had a second and third line of treatment, respectively. Median OS was 14.5 months.

Conclusions

Advanced cHCC-ICC appear to be aggressive tumors with a poor prognosis. Cirrhosis was associated in one third of cases. Systemic treatments are not standardized and must be evaluated in a dedicated study.

Clinical trial identification

Legal entity responsible for the study

Dr. Yann Touchefeu

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.